RPTX - Repare Therapeutics Inc

2.65
0.020   0.755%

Share volume: 1,219,919
Last Updated: 01-27-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$2.63
0.02
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 47%
Dept financing 21%
Liquidity 58%
Performance 36%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
23.83%
6 Months
46.41%
1 Year
130.43%
2 Year
-50.74%
Key data
Stock price
$2.65
P/E Ratio 
0.00
DAY RANGE
$2.62 - $2.65
EPS 
-$2.13
52 WEEK RANGE
$0.89 - $2.66
52 WEEK CHANGE
$134.51
MARKET CAP 
75.608 M
YIELD 
N/A
SHARES OUTSTANDING 
42.986 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
1.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Lloyd M. Segal
Region: US
Website: reparerx.com
Employees: 180
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach. Its lead product candidate is an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Recent news